01
Contributed article · Express Pharma
From capacity to capability: Five proofs for India’s pharma future
Varun Sharma · 7 Sep 2026Varun Sharma
Building accountable operating systems for medicines.
Founder of NEUVIOR and the VARUNÉ portfolio. CEO & CTO of NEUVIOR and product architect of PHARMORIS. Building medicines intelligence, with wider ambitions across biosystems, space systems, AI and robotics.
Current focus: NEUVIOR and PHARMORIS · Standard: evidence, ownership and traceability before speed
Varun Sharma · 7 Sep 2026
02Podcast appearance · AI Ethics Now · University of Warwick IATL
AI and Accountability: When Does a Suggestion Become a Decision?
Varun Sharma · 23 Aug 2026
03Contributed views and analysis · pharmaphorum
Approval is not access: Pilots’ real test is implementation
Varun Sharma · 18 Aug 2026Publication and podcast participation are evidence of publication—not endorsement, deployment, product validation or commercial outcome.
Current work. Clear stage.
Current operating work and long-term theses are kept distinct.
Evidence-led infrastructure for medicines decisions.
NEUVIOR is building medicines intelligence around evidence, human judgement and accountable follow-through.
Operating company · NEUVIOR PHARMACEUTICALS LTD · SC857853
PHARMORIS
A human-governed operating system for medicines work.
A staff-facing system in controlled, non-production development for reviewable evidence and accountable action.
Controlled development · Not presented as deployed or clinically validated
SourceDecisionRecord
View product status Selected non-dilutive innovation support.
NEUVIOR has been selected for non-dilutive support for defined R&D project work. This site links only project-level information already in the public domain. Maximum award value, eligible project cost, company contribution and cash received are different facts; Award ceilings and eligible project costs are not cash received, revenue, customer adoption or outcomes.
Support record and boundariesInnovate UK project; the public project record is closed.
VIONIX ZERO UKRI recordInnovate UK project; the public project record is closed.
PHARMORIS UKRI recordNEUVIOR’s 2025–26 NHS DSP Toolkit submission; not an NHS endorsement.
DSP Toolkit recordReviewed 8 September 2026 · Source, status and limitations remain visible.
The operating instinct.
“My dad’s corner shop taught me that systems only matter when they work for the person standing in front of you.”
Glasgow-born and British-Indian, Varun began with the practical logic of family business: listen closely, keep promises visible and solve the problem in front of you. He now applies that instinct to medicines, technology and the institutions around them.
Public voice — neurodivergent entrepreneurship · medicines access · accountable innovation
Read the biography
Medicines first. A wider ambition ahead.
Building a founder-led portfolio across medicines, biological research, space and intelligence.
NEUVIOR and PHARMORIS
Operating company and controlled product development.
VARUNÉ Biosystems and VARUNÉ Labs
Five peer biological research pillars, alongside a separate Labs programme for medicines, formulations and personal care operated by NEUVIOR.
VARUNÉ Space Systems and VARUNÉ Intelligence
Precommercial space systems ambition, with a separate exploratory direction in AI and robotics for complex real-world problems.
VARUNÉ Group is the portfolio brand. Each company and programme retains its own identity and stage.
Selected public record.
Commentary, appearances and publisher-written coverage are labelled by type. Publication is not proof of independent sourcing, deployment or endorsement.
Contributed articleExpress PharmaFrom capacity to capability: Five proofs for India’s pharma futurePodcast appearanceAI Ethics Now · University of Warwick IATLAI and Accountability: When Does a Suggestion Become a Decision?Contributed views and analysispharmaphorumApproval is not access: Pilots’ real test is implementationContributed opinionTechRadar ProFive questions to test whether an AI stack is truly under your controlContributed commentaryETPharmaIndia’s pharma quality reset will be won after the inspector leavesPublished letterFinancial TimesLetter: The real test is whether invention leads to adoptionExpert commentaryPharmaceutical TechnologyWhy the India-UK trade deal now needs a five-gate implementation ledger